Marina Inks Partnership for Bladder Cancer Program

Under the terms of the deal, Debiopharm will have “full responsibility for the development and commercialization of any products arising from the partnership,” the companies said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.